Shares of Inovio Pharmaceuticals Inc. INO shed 5.26% to $1.98 Friday, on what proved to be an all-around dismal trading ...

Inovio Pharmaceuticals Inc. closed $12.66 below its 52-week high ($14.75), which the company reached on April 1st.

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Inovio Pharmaceuticals (INO – Research Report) today and set a price target of ...

Inovio Pharmaceuticals Inc (INO) stock saw a decline, ending the day at $2.09 which represents a decrease of $-0.19 or -8.33% from the prior close of $2.28. The stock opened at $2.36 and touched a low ...

Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.

Stephens has recently initiated Inovio Pharmaceuticals Inc (INO) stock to Overweight rating, as announced on May 14, 2024, according to Finviz. Earlier, on January 25, 2024, Oppenheimer had raised the ...

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovio (INO) highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings, with ...

INO has been the subject of a number of research analyst reports. Royal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...